TC-I 15
Based on 3 publication(s) in Google Scholar
TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.94%
- CAS. Nr.: 916734-43-5
- Formel: C23H28N4O6S2
- Molecular Weight:520.62
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) TC-I 15
More-
WB
-
Flow Cytometry
Biologische Aktivität
|
α2β1 0.4 (α2β1 μM (IC50) |
α2β1 26.8 (α2β1 μM (IC50) |
α1β1 23.6 (α1β1 μM (IC50) |
α1β1 24.4 (α1β1 μM (IC50) |
α11β1 177 (α11β1 μM (IC50) |
α11β1 3177 (α11β μM (IC50) |
TC-I 15 (0-500 μM, 1 h) inhibits the adhesion of C2C12 cells expressing α2β1 in a dose-dependent manner, with IC50 values of 26.8 μM and 0.4 μM for GFOGER and GLOGEN, respectively[1].
TC-I 15 (0-500μM, 1 h) also inhibited α1β1, showing IC50 values of 23.6 μM for GFOGER and 24.4 μM for GLOGEN[1].
TC-I 15 (0-50μM, 1 h) inhibits the adhesion of HT1080 cells to GFOGER[1].
TC-I 15 (0-50μM, 1 h) inhibits the uptake of EVs by LFs cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LFs
-
Concentration:0, 0.5, 1, 2 μM
-
Incubation Time:1 h
-
Result:Inhibited LFs uptake of EVs, inhibited LF activation induced by EVs, and inhibited the expression of p-Smad3 and POSTN.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 J mice[2]
-
Dosage:10 μg; every other day for 3 weeks; once every 2 weeks for 3 weeks
-
Administration:Intravenous injection (i.v.)
-
Result:Inhibited the formation of pre-metastatic microenvironment induced by EVs, inhibited SACC lung metastasis induced by EVs, and significantly increased integrin β1 of EVs.
Chemical Information
-
CAS. Nr. 916734-43-5
-
Appearance Solid
-
Molecular Weight 520.62
-
Formel C23H28N4O6S2
-
Color White to off-white
-
SMILES
O=[S](N(CSC(C)1C)[C@@H]1C(N[C@H](C(O)=O)CNC(NCC2=CC=CC=C2)=O)=O)(C3=CC=CC=C3)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
Targeting the HSP47-collagen axis inhibits brain metastasis by reversing M2 microglial polarization and restoring anti-tumor immunity. [Abstract]2024 May 7:101533. PMID: 38744278
TC-I 15 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 May 7:101533. [Abstract]
COL1-treated BV2 cells were treated with TC-I-15. Cell lysates were analyzed by Western blotting, and the levels of selected cytokine genes were detected by RT-qPCR.
TC-I 15 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 May 7:101533. [Abstract]
BV2 cells treated with COL1 were transfected with p65 siRNA or treated with TC-I-15, and the expression of CD206 was analyzed by flow cytometry.
-
Alzheimers Dement
Nanoplastics trigger glial-neuronal collagen signaling miscommunication to exacerbate cognitive impairment in Alzheimer's disease. [Abstract]2026 Jan;22(1):e71096. PMID: 41566532 -
Biosci Rep
Tubulogenesis of bovine uterine glands by epidermal growth factor and collagen I in 3D culture systems. [Abstract]2026 Jun 17;46(6):BSR20260010. PMID: 41952664
Lösungsmittel & Löslichkeit
DMSO : 250 mg/mL (480.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% PBS
Solubility: 10 mg/mL (19.21 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Emma J. Hunter, Selectivity of the collagen-binding integrin inhibitors, TC-I-15 and obtustatin. Toxicol Appl Pharmacol. 2021 Oct 1;428:115669. [Content Brief]
[2]. Jing Kong, et al. Extracellular vesicles of carcinoma-associated fibroblasts creates a pre-metastatic niche in the lung through activating fibroblasts. Mol Cancer. 2019 Dec 3;18(1):175. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9208 mL | 9.6039 mL | 19.2079 mL | 48.0197 mL |
| 5 mM | 0.3842 mL | 1.9208 mL | 3.8416 mL | 9.6039 mL | |
| 10 mM | 0.1921 mL | 0.9604 mL | 1.9208 mL | 4.8020 mL | |
| 15 mM | 0.1281 mL | 0.6403 mL | 1.2805 mL | 3.2013 mL | |
| 20 mM | 0.0960 mL | 0.4802 mL | 0.9604 mL | 2.4010 mL | |
| 25 mM | 0.0768 mL | 0.3842 mL | 0.7683 mL | 1.9208 mL | |
| 30 mM | 0.0640 mL | 0.3201 mL | 0.6403 mL | 1.6007 mL | |
| 40 mM | 0.0480 mL | 0.2401 mL | 0.4802 mL | 1.2005 mL | |
| 50 mM | 0.0384 mL | 0.1921 mL | 0.3842 mL | 0.9604 mL | |
| 60 mM | 0.0320 mL | 0.1601 mL | 0.3201 mL | 0.8003 mL | |
| 80 mM | 0.0240 mL | 0.1200 mL | 0.2401 mL | 0.6002 mL | |
| 100 mM | 0.0192 mL | 0.0960 mL | 0.1921 mL | 0.4802 mL |